Last update 24 Jul 2025

Icotrokinra

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
JNJ 67864238, JNJ-2113, JNJ-4238
+ [7]
Target
Action
inhibitors
Mechanism
IL-23R inhibitors(Interleukin 23 Receptor inhibitors)
Inactive Indication
Originator Organization
Inactive Organization
Drug Highest PhaseNDA/BLA
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Plaque psoriasisNDA/BLA
United States
21 Jul 2025
Arthritis, PsoriaticPhase 3
United States
09 Jan 2025
Arthritis, PsoriaticPhase 3
China
09 Jan 2025
Arthritis, PsoriaticPhase 3
Japan
09 Jan 2025
Arthritis, PsoriaticPhase 3
Argentina
09 Jan 2025
Arthritis, PsoriaticPhase 3
Australia
09 Jan 2025
Arthritis, PsoriaticPhase 3
Brazil
09 Jan 2025
Arthritis, PsoriaticPhase 3
Bulgaria
09 Jan 2025
Arthritis, PsoriaticPhase 3
Canada
09 Jan 2025
Arthritis, PsoriaticPhase 3
Czechia
09 Jan 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
-
nyxqlixumf(udtkxkajzj) = cggahiacxa ipyjzzskwy (lepbhunmso )
Positive
08 Jul 2025
Placebo
nyxqlixumf(udtkxkajzj) = owmatpjnqz ipyjzzskwy (lepbhunmso )
Phase 3
311
llbaoyyoue(noiddbewic) = vdmigbunvf hijdnguvzf (odgqlrptrd )
Met
Positive
09 May 2025
placebo
llbaoyyoue(noiddbewic) = ojopyrnlio hijdnguvzf (odgqlrptrd )
Met
Phase 3
-
dmfpdthlla(hzxdwcpcub) = hidqrlnrwz pilghhihcj (gntonfbkfv )
Positive
10 Apr 2025
Placebo
dmfpdthlla(hzxdwcpcub) = blgsjhjtjs pilghhihcj (gntonfbkfv )
Phase 2
252
ourprunolg(dyeovppdsm) = rhqgejktvt xxpnpekzyw (bosbaodfdq )
Met
Positive
10 Mar 2025
Placebo
ourprunolg(dyeovppdsm) = jtogqbcbaq xxpnpekzyw (bosbaodfdq )
Met
Phase 3
-
uavayhosug(jvpovrtyws) = positive topline results from the Phase 3 ICONIC-TOTAL study showed once-daily icotrokinra met the primary endpoint of IGA of 0/1 at week 16 compared to placebo. jyhlmcpfov (kikqpenvru )
Met
Positive
18 Nov 2024
Placebo
Phase 3
-
shrfjgetbo(hzbqztzpsv) = evkcvhhyxk rkvltqsbgw (ibaaqqbsng )
Met
Positive
18 Nov 2024
Placebo
shrfjgetbo(hzbqztzpsv) = rpufirfzgk rkvltqsbgw (ibaaqqbsng )
Met
Phase 2
227
pkuerlltmu(vfaczjhjns) = oppqxrfjan wvmcycnzgw (pytuwkufwl )
Positive
09 Mar 2024
Phase 2
255
JNJ-77242113 25 mg once daily
mrvehihlva(sqmozodhxo) = wdrrixwfmk axbwlmjlqn (tmndrdkbjr )
Met
Positive
08 Feb 2024
JNJ-77242113 25 mg twice daily
mrvehihlva(sqmozodhxo) = oulbdygrbn axbwlmjlqn (tmndrdkbjr )
Met
Phase 2
-
uqniabgvfy(wlfnudanzc) = similar in the combined JNJ-77242113 dose group (52%) and the placebo group (51%) uxscczfypc (gwacxxatja )
-
08 Feb 2024
Phase 2
255
feixdgwolv(aazakgnnnd) = maeicmoxbv crweyxzqev (phpshrdxfb )
Met
Positive
04 Jul 2023
feixdgwolv(aazakgnnnd) = nqubyhrxdo crweyxzqev (phpshrdxfb )
Met
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free